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Abstract 17 
Aims: Since the role of the major mitochondrial NAD+-dependent deacetylase, sirtuin 3 (Sirt3), 18 
is differential in cancer, opposite to the well-known tumor-suppressing effect of hyperoxia, 19 
this study aimed to investigate the role of Sirt3 in triple-negative breast cancer (TNBC) cell 20 
line MDA-MB-231 upon hyperoxic (95% O2) conditions. 21 
Main methods: MDA-MB-231 cells were stably transfected with Flag-tagged Sirt-3 or empty 22 
plasmid. Western blot and real-time PCR were used to monitor the expression of proteins or 23 
genes involved in mitochondrial biogenesis, metabolic regulation and antioxidant defense. 24 
Immunocytochemistry and confocal microscopy were used to confirm the cellular localization 25 
and abundance of proteins. Flow cytometry was used to analyze mitochondrial mass, 26 
potential and ROS production, and MTT test as a measure of metabolic activity. Mitotic index 27 
analysis, colony-forming unit assay, DNA damage and Annexin V-FITC analyses were used to 28 
assess the differences in the growth and apoptosis rate.  29 
Key findings: Although Sirt3 seemed to improve mitochondrial properties by increasing 30 
mitochondrial mass and potential, metabolic activity (Warburg effect) and antioxidative 31 
defense (SOD2, Cat), it also increased mitochondrial ROS, induced DNA damage, timp-1 32 
expression, formation of multinucleated cells and apoptosis, and finally markedly reduced the 33 
proliferation of MDA-MB-231 cells. All these effects were even more evident upon the 34 
hyperoxic treatment, thus pointing towards combined negative effect of Sirt3 and hyperoxia 35 
on MDA-MB-231 cells. 36 
Significance: Both Sirt3 and hyperoxia, alone or in combination, have the potential to 37 
negatively affect the malignant properties of the MDA-MB-231 cells and should be further 38 
explored as a possible therapy for TNBC. 39 
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Introduction 44 
Breast cancer is the most common malignant tumor in women and the third cause of death 45 
in the world [1]. Numerous studies focus on triple-negative breast cancer (TNBC) cells, which 46 
are more aggressive and resistant to endocrine therapy since they lack the expression of 47 
estrogen and progesterone receptor and human epidermal growth factor type 2 [2]. 10-15% 48 
of breast cancer patients suffer from TNBC and have a much worse treatment outcome 49 
compared to other breast cancer subtypes [3]. For this reason, there has been an interest in 50 
further research at the molecular level to obtain a more accurate diagnosis and possible 51 
treatment therapies.  52 
Oxidative stress occurs as a result of high levels of reactive oxygen species (ROS) and is defined 53 
as a disturbance of the balance between ROS production and antioxidant defense [4,5]. 54 
Numerous studies confirm that tumor cells typically exhibit higher levels of ROS than healthy 55 
cells, and high levels of ROS induce DNA damage and genomic instability, resulting in the 56 
continued growth and proliferation of tumor cells, as well as resistance to chemotherapy [6–57 
8]. In addition to being a consequence of common biochemical processes, ROS are products 58 
of increased oxygen concentration in the cell caused by hyperoxia. Thereby, hyperoxia-59 
induced ROS levels could be certainly toxic for cancer cells and could impair tumor growth, 60 
i.e. reduce tumor aggressive behavior [9,10]. Also, some studies have confirmed a smaller 61 
number of TNBC metastases under hyperoxic conditions [11].  62 
The mammalian sirtuin (Sirt) family is described with seven proteins (Sirt1-7), three of which 63 
are the mitochondrial sirtuins (Sirt3-5) [12]. Sirt3 is a major mitochondrial NAD+-dependent 64 
deacetylase with an essential role in maintaining energy homeostasis [13]. In the absence of 65 
Sirt3 the mitochondrial proteins become hyperacetylated, thus reducing the mitochondrial 66 
ability to generate ATP and elevating oxidative stress (reviewed in [14]). As a defense strategy 67 
against oxidative damage caused by ROS, the cells most commonly use the enzymatic 68 
antioxidants superoxide dismutase (SOD), catalase (Cat), glutathione peroxidase and 69 
glutathione reductase [15]. Sirt3 plays a key role in the deacetylation and activation of some 70 
of these antioxidant enzymes, with SOD2 as one of the main targets. However, the role of 71 
Sirt3 in breast cancer is still controversial [8].  72 
Due to the known tumor-suppressing effect of hyperoxic treatment and a differential role of 73 
Sirt3 in cancer, this study aimed to investigate the role of increased expression of the Sirt3 74 
upon hyperoxia on morphology, proliferation, cell cycle, metabolic activity, DNA damage, 75 
apoptosis and mitochondrial function of TNBC cells MDA-MB-231. We found that, although 76 
Sirt3 seemed to improve several mitochondrial properties and antioxidative defense, it also 77 
increased mitochondrial ROS, induced DNA damage, apoptosis, formation of multinucleated 78 
cells, and significantly diminished the proliferation of MDA-MB-231 cells. These effects were 79 
even more pronounced upon the hyperoxic treatment, thus pointing towards a combined 80 
negative effect of Sirt3 and hyperoxia on MDA-MB-231 cells. Therefore, both Sirt3 and 81 
hyperoxia have the potential to negatively modulate the malignant properties of the MDA-82 
MB-231 cells and should be further explored as a possible therapy for TNBC. 83 
Materials and Methods 84 
Cell culture and transfection 85 
In the present study, adherent, epithelial, basal-like triple-negative breast cancer cell line 86 
MDA-MB-231 (ATCC® HTB-26™; Manassas, VA, USA) was used. Cells were transfected with 87 
the pcDNA3.1+ Flag-Sirt3 plasmid containing the Flag-tagged Sirt3 gene (Addgene 88 
Cat.No.13814) as described previously [16], and are marked as MDA-S3. Cells transfected with 89 
the empty plasmid pcDNA3.1+ were used as control (MDA-C). The cells were grown in 90 
complete high glucose (4.5 g/L) Dulbecco's modified Eagle's medium (DMEM; Sigma Aldrich, 91 
St. Louis, MO, USA) with the addition of 10% fetal bovine serum (FBS; Capricorn Scientific 92 
GmbH, Ebsdorfergrund, Germany), 1% non-essential amino acids (Capricorn Scientific GmbH, 93 
Ebsdorfergrund, Germany) and 1% antibiotic/antimycotic solution (Capricorn Scientific 94 
GmbH, Ebsdorfergrund, Germany). 95 
Normoxic and hyperoxic conditions 96 
After seeding, the cells were allowed to adhere for 24 h and then treated in normoxic or 97 
hyperoxic conditions (95% O2). To achieve hyperoxic conditions, cells were kept in a self-98 
contained and sealed hyperoxic chamber (StemCellTM Technology Inc., Vancouver, Canada) 99 
for 16 h in an incubator at 37°C, together with control cells (normoxia) under standard 100 
conditions (37°C, 5% CO2).  101 
RNA isolation and real-time PCR 102 
After treatment (hyperoxic and normoxic), the cells were collected in Trizol Reagent (Life 103 
Technologies, Carlsbad, CA, USA) for RNA extraction according to the manufacturer’s 104 
recommendations. The RNA was quantified using the Nanodrop (NanoPhotometer N60/N50, 105 
Implen GmbH, München, Germany) and treated with DNAase (TURBO DNA-free Kit, Thermo 106 
Fisher Scientific, Waltham, MA, USA), followed by reverse transcription (Applied Biosystems™ 107 
High-Capacity cDNA Reverse Transcription Kit; Foster City, CA, USA). Taqman assays (Thermo 108 
Fisher Scientific, Waltham, MA, USA) for sirt3 (Hs00953477_m1), timp-1 (Hs01092512_g1) 109 
and β-actin (Hs01060665_g1) genes were used for real-time PCR performed on a 7300 Real-110 
time PCR system device (Applied Biosystems, Foster City, CA, USA) using a comparative CT (2-111 
ΔΔCt) method to determine the relative gene expression level.  112 
Protein isolation and Western blot 113 
After hyperoxic treatment, cells were trypsinized (Capricorn Scientific, Ebsdorfergrund, 114 
Germany), collected and centrifuged, and the cell pellet was resuspended in RIPA buffer (50 115 
mM Tris buffer, 150 mM NaCl, 0.1% SDS, 12 mM Na-deoxycholate, 1% Triton) with protease 116 
inhibitors (cOmpleteTM EDTA-free EASYpack, Roche, Basel, Switzerland). The lysate was 117 
sonicated (amplitude 80%; Labsonic, Biotech International Ltd., Delhi, India) and centrifuged 118 
for 20 min at 16000 g (4°C) and the supernatant was transferred to a new tube, from which 119 
the protein concentration was measured with Pierce™ BCA Protein Assay Kit (Thermo Fischer 120 
Scientific, Waltham, MA, USA). The proteins were prepared in SDS-PAGE sample buffer (100 121 
mM Tris-HCl (pH 6,8), 2% SDS, 20% glycerol, 4% β-mercaptoethanol, 0,5% bromophenol blue 122 
dye) and Western blot analysis was carried out as described previously [16]. Antibodies used 123 
in this study are listed in Table 1. 124 
Table 1. Antibodies used for Western blot analyses 125 
Antibody Dilution Host Manufacturer 
Sirt3 (F-10, sc-365175) 1:500 Mouse 
Santa Cruz 
Biotechnology, USA 
Catalase (ab1877) 1:1000 Rabbit Abcam, UK 
Gamma H2A.X (phospho S139, 
ab11174) 
1:8000 Rabbit Abcam, UK 
SOD2 (ab13533) 1:2000 Rabbit Abcam, UK 
Sirt1 (NBP2-27205) 1:300 Rabbit Novus Biologicals, USA 
Ldh-A (sc-33781) 1:200 Rabbit 
Santa Cruz 
Biotechnology, USA 
PGC-1α (NBP1-04676) 1:1000 Rabbit Novus Biologicals, USA 
Anti-mouse (170-6516) 1:5000 Goat  Bio-rad, USA 
Anti-rabbit (NA934) 1:5000 Goat  GE Healthcare, USA 
 126 
MTT and CFU assays 127 
For the MTT assay, 5000 cells were seeded into 96-well plates. After hyperoxic treatment, the 128 
plates were left for an additional 48 h in the incubator under normal conditions and then 129 
processed as described previously [16]. For the colony-forming unit (CFU) assay, 1500 cells 130 
were seeded per Petri dish (6 cm). After hyperoxic treatment, the cells were left for 10 days 131 
until visible colonies were formed and the plates were processed as described previously [16]. 132 
Flow cytometry analysis of mitochondrial parameters, ROS and apoptosis  133 
Mitotracker Deep Red dye (100 nM; Thermo Fisher Scientific, Waltham, MA, USA) was used 134 
for mitochondrial membrane potential (ΔΨ) analysis, and NAO (0,5 nM; 10-N-nonyl acridine 135 
orange, Invitrogen, Carlsbad, CA, USA) for mitochondrial mass. DHE dye (20 µM; 136 
dihydroethidium, Sigma Aldrich, St. Louis, MO, USA) was used to measure cytosolic ROS and 137 
MitosoxRed (5 µM; Thermo Fisher Scientific, Waltham, MA, USA) to detect mitochondrial 138 
ROS. ApoScreen™ Annexin V Apoptosis Kit (SouthernBiotech, Birmingham, AL, USA) was used 139 
according to the manufacturer's protocol for apoptosis analysis. After hyperoxic treatment, 140 
the cells were trypsinized and collected, washed with 1x PBS, distributed (300000 141 
cells/sample) into FACS tubes, resuspended in each dye and incubated for 30 min at 37°C 142 
(those for apoptosis 15 min in dark at room temperature (RT) followed by analysis on FACS 143 
within 1 h). After the incubation, all the cells except those in the DHE solution were 144 
centrifuged, washed with 1x PBS and resuspended in 1x PBS + 1% FCS. Propidium iodide (PI) 145 
at a concentration of 1.5 μg/mL was added to tubes with NAO and Mitotracker Deep Red to 146 
exclude dead cells, whereas 500 nM Sytox Red (Thermo Fisher Scientific, Waltham, MA, USA) 147 
was used with DHE and MitosoxRed for the same purpose. The samples were analyzed on a 148 
flow cytometer (FACSCalibur, BD Biosciences, Franklin Lakes, NJ, USA) in FL1 (NAO and 149 
annexin), FL2 (DHE and MitosoxRed), FL3 (PI) and FL4 (Mitotracker Deep Red and Sytox Red) 150 
channel. The data analysis was performed using the FCS Express 7 software package (De Novo 151 
software, Pasadena, CA, USA). 152 
Mitotic index analysis 153 
After hyperoxic treatment, the medium from the cells was collected in tubes, the cells were 154 
trypsinized and collected by pooling with appropriate medium, washed twice with 1x PBS and 155 
resuspended in cold 1x PBS, followed by dropwise addition of -20°C pre-cooled 96% EtOH on 156 
a mild vortex. Samples were stored at -20°C until the day of the experiment (minimum for 6 157 
h). Samples were centrifuged and the cell pellet was washed with 1x PBS, centrifuged again, 158 
and the resulting pellets were resuspended in 1x buffer (1% FCS and 0.1% Triton X-100 in 1x 159 
PBS), centrifuged, and resuspended in primary anti-phosho-Histone H3 (Ser 10) antibody 160 
(1:200; Cat. No. 06-570; Merck Millipore, Burlington, MA, USA) prepared in 1x buffer and 161 
incubated for 1 h at RT. Afterward the pellets were washed with 1x buffer and incubated for 162 
1 h at RT in dark with a secondary antibody (Alexa488, 1:1000; A-11001, Thermo Fisher 163 
Scientific, Waltham, MA, USA), followed by two washes with 1x buffer. Cells were finally 164 
resuspended in 0.1 µg/μL RNase A (iNtRON Biotechnology, Seongnam, South Korea) and 50 165 
μg/μL propidium iodide (PI) solution, and FACS analysis was performed (FACSCalibur, BD 166 
Biosciences, Franklin Lakes, NJ, USA).  167 
SOD activity analysis 168 
For superoxide dismutase (SOD) activity analysis, the RANSOD kit (RANDOX Labs, Crumlin, UK) 169 
was used according to the manufacturer's protocol, as described previously [17]. 170 
Immunocytochemistry, fluorescence and confocal microscopy analysis 171 
Immunocytochemistry staining was performed as described previously [16,17]. MitoTracker 172 
Deep Red (100 nM; Thermo Fisher Scientific, Waltham, MA, USA) was added after hyperoxic 173 
treatment and cells were incubated for 20 min at 37°C. Primary and secondary antibodies 174 
used for immunocytochemistry in this study are listed in Table 2. Confocal imaging was 175 
performed using Leica TCS SP8 X laser scanning microscope (Leica Microsystems, Wetzlar, 176 
Germany), equipped with an HC PL APO CS2 63/1.40 oil immersion objective and a white light 177 
laser. The excitation wavelengths and emission detection ranges used were 405 nm and 412–178 
460 nm for DAPI, 488 nm and 495-550 nm for Alexa488, 594 nm and 601-644 nm for Alexa594, 179 
and 644 nm and 651–700 nm for MitoTracker Deep Red, respectively. For cell morphology 180 
analysis on EVOS Floid Cell Imaging Station (Thermo Fisher Scientific, USA), live cells in the 181 
medium were stained with NAO (1,5 µM) and Hoechst 33342 (5 µg/ml; Thermo Fisher 182 
Scientific, USA) for 5 min, washed 2x with 1x PBS and maintained in 1x PBS+Mg/Ca.  183 
Table 2. Antibodies used for immunofluorescence analyses 184 
Antibody Dilution Host Manufacturer 
Sirt3 (F-10, sc-365175) 1:100 Mouse Santa Cruz Biotechnology, USA 
Gamma H2A.X (phospho 
S139, ab11174) 
1:5000 Rabbit Abcam, UK 
Anti-mouse Alexa 488 (A-
11001) 
1:2000 Goat Thermo Fisher Scientific, USA 
Anti-rabbit Alexa 594 (A-
11012) 
1:1000 Goat Thermo Fisher Scientific, USA 
 185 
Statistical analysis 186 
Statistical analysis of data was performed using SPSS (17.0, IBM, Armonk, NY, USA) for 187 
Windows as described previously [17]. Significance is set at p<0.05. 188 
Results 189 
Overexpressed Sirt-3 is localized in mitochondria and its expression is increased upon 190 
hyperoxic treatment in MDA-MB-231 cells. MDA-MB-231 cells with stably transfected 191 
pcDNA3.1+ Flag-Sirt3 plasmid were defined as MDA-S3, and cells with stably transfected 192 
empty plasmid pcDNA3.1+ as MDA-C (control). Since Sirt3 is a major mitochondrial NAD+-193 
dependent deacetylase [13], first we aimed to confirm its expression and localization in the 194 
transfected cells. Confocal microscopy analysis confirmed overexpressed Sirt3 and its 195 
localization in mitochondria of MDA-S3 cells, unlike MDA-C cells (Figure 1A). The results of 196 
the qPCR analysis showed that MDA-S3 cells have a 19-fold higher expression of the sirt3 gene 197 
than MDA-C in normoxia, and as much as 38-fold higher in hyperoxia (Figure 1B). Western 198 
blot analysis did not detect Sirt3 protein expression in the MDA-C cells, while it was visible in 199 
the MDA-S3 as a 28 kDa band (Figure 1C, D), with a stronger signal in hyperoxia, which is 200 
consistent with the results of gene expression. Thus, we can conclude that Sirt3 was 201 
successfully transfected into MDA-MB-231 cells, and that its expression is upregulated in 202 
hyperoxic conditions.  203 





Figure 1. Overexpressed Sirt-3 is localized in mitochondria and its expression is 209 
increased upon hyperoxic treatment in MDA-MB-231 cells. (A) Representative 210 
confocal image of Sirt3 (green) in mitochondria (red; Mitotracker Deep Red). Nuclei 211 
were detected with DAPI (blue). Overlay image shows overlap (yellow) of the Sirt3 and 212 
mitochondria staining. (B) Real-time PCR analysis of sirt3 gene expression in MDA-C 213 
and MDA-S3 cells under normoxic and hyperoxic conditions: MDA-S3 vs. MDA-C 214 
(ap<0.001), hyperoxia vs. normoxia (**p<0.01). Data are presented as fold-change ± 215 
S.E., and normalized to control group. β-actin was used as the endogenous control. 216 
(C) Densitometry analysis of Sirt3 protein expression in MDA-C and MDA-S3 cells 217 
under normoxic and hyperoxic conditions: MDA-S3 vs. MDA-C (ap<0.001), MDA-S3 in 218 
hyperoxia vs. normoxia (**p<0.01). Data are presented as mean ± S.D. (D) 219 
Representative immunoblot of Sirt3 protein expression in MDA-C and MDA-S3 cells 220 
under normoxic and hyperoxic conditions. Amido black was used as a loading control. 221 
Experiments were repeated at least three times and representative data are shown.  222 
Overexpressed Sirt-3 is associated with hyperoxia-induced alterations in mitochondrial 223 
mass and potential in MDA-MB-231 cells. Since Sirt3 is a mitochondrial protein involved in 224 
the regulation of mitochondrial mass and potential [18,19], these parameters were analyzed 225 
by flow cytometry with the use of NAO and Mitotracker Deep Red dyes, respectively. Sirt3 226 
expression caused an increase of mitochondrial mass in normoxia, which was further 227 
enhanced by hyperoxic treatment (Figure 2A). On the other hand, higher mitochondrial 228 
potential in MDA-S3 cells in normoxia was reduced in both control and MDA-S3 cells upon 229 
hyperoxia (Figure 2B). Thus, we can conclude that Sirt3 increases both mitochondrial mass 230 
and potential, whereas hyperoxia has an inducing effect on mitochondrial mass and reducing 231 
effect on mitochondrial potential.  232 
 233 
Figure 2. Overexpressed Sirt-3 is associated with hyperoxia-induced alterations in 234 
mitochondrial mass and potential in MDA-MB-231 cells. (A) Mitochondrial mass of 235 
MDA-C and MDA-S3 cells under normoxic and hyperoxic conditions measured with 236 
NAO dye: MDA-S3 vs. MDA-C (ap<0.001), MDA-S3 hyperoxia vs. normoxia 237 
(***p<0.001). (B) Mitochondrial potential of MDA-C and MDA-S3 cells under normoxic 238 
and hyperoxic conditions measured with Mitotracker Deep Red dye: MDA-S3 vs. MDA-239 
C (ap<0.001), hyperoxia vs. normoxia (***p<0.001). Data show the relative 240 
fluorescence intensity as the average geometric mean ± SD. Experiments were 241 
repeated at least three times and representative data are shown. 242 
Overexpressed Sirt3 affects metabolic activity and proteins involved in metabolism with the 243 
reverse effect of hyperoxic treatment on Ldh-A expression in MDA-MB-231 cells. Because in 244 
our study Sirt3 increased several mitochondrial parameters, we next analyzed the metabolic 245 
activity of transfected cells by MTT test and expression of several proteins involved in 246 
metabolic regulation (Sirt1, Ldh-A, PGC-1α). The MTT test results showed an increase of 247 
metabolic activity in MDA-S3 cells in both normoxic and hyperoxic conditions compared to 248 
MDA-C cells (Figure 3A), which was accompanied by a similar pattern of Sirt1 expression 249 
(Figure 3B, E), a protein involved in the regulation of metabolic responses as well as in DNA 250 
damage response [20,21]. The observed higher metabolic activity of MDA-S3 cells was in 251 
normoxic conditions also followed by increased expression of lactate dehydrogenase (Ldh-A; 252 
Figure 3C, E), a marker of aerobic glycolysis [22]. However, hyperoxic treatment had the 253 
opposite effect on its expression, thus MDA-S3 cells had lower Ldh-A expression than MDA-C 254 
cells. Expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha 255 
(PGC-1α), one of the key regulators of energy metabolism [23], was lower in MDA-S3 cells in 256 
both normoxia and hyperoxia compared to MDA-C cells (Figure 3D, E). Overall, we can 257 
conclude that Sirt3 affects the metabolic activity and the expression of all studied proteins 258 
involved in the metabolism of MDA-MB-231 cells, whereas hyperoxic treatment impacts the 259 
expression of Ldh-A and Sirt1 proteins. 260 
 261 
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Figure 3. Overexpressed Sirt3 affects metabolic activity and proteins involved in 263 
metabolism with the reverse effect of hyperoxic treatment on Ldh-A expression in 264 
MDA-MB-231 cells. (A) Metabolic activity of MDA-C and MDA-S3 cells under normoxic 265 
and hyperoxic conditions measured by MTT test: MDA-S3 vs. MDA-C (ap<0.001). (B) 266 
Densitometry analysis of Sirt1 protein expression in MDA-C and MDA-S3 cells under 267 
normoxic and hyperoxic conditions: MDA-S3 vs. MDA-C (ap<0.01), hyperoxia vs. 268 
normoxia (*p<0.05). (C) Densitometry analysis of Ldh-A protein expression in MDA-C 269 
and MDA-S3 cells under normoxic and hyperoxic conditions: MDA-S3 vs. MDA-C 270 
(ap<0.01), MDA-C hyperoxia vs. normoxia (*p<0.05), MDA-S3 hyperoxia vs. normoxia 271 
(**p<0.01). (D) Densitometry analysis of PGC-1α protein expression in MDA-C and 272 
MDA-S3 cells under normoxic and hyperoxic conditions: MDA-S3 vs. MDA-C (ap<0.01). 273 
Data are presented as mean ± S.D. Experiments were repeated at least three times 274 
and representative data are shown. (E) Immunoblots of Sirt1, Ldh-A and PGC-1α 275 
protein expression in MDA-C and MDA-S3 cells under normoxic and hyperoxic 276 
conditions. Amido black was used as a loading control. 277 
Overexpressed Sirt3 is not associated with a hyperoxic effect on ROS production and 278 
antioxidative enzymes in MDA-MB-231 cells. Since hyperoxia is a well-known inducer of ROS 279 
[24], mitochondrial (mtROS) and cytosolic ROS (cytoROS) production was analyzed using 280 
MitosoxRed and DHE dyes, respectively. We observed that MDA-S3 cells had higher mtROS in 281 
both normoxia and hyperoxia (Figure 4A), with no change in cytoROS compared to control 282 
cells (Figure 4B). Hyperoxic treatment increased the production of mtROS (Figure 4A) and 283 
cytoROS (Figure 4B) in both MDA-C and MDA-S3 cells. Due to the observed higher levels of 284 
ROS induced by either Sirt3 or hyperoxic treatment, we also analyzed the antioxidative status 285 
of transfected cells. MnSOD (SOD2) and CuZnSOD (SOD1) activities were analyzed, as well as 286 
the expression of SOD2 and catalase (Cat) proteins. SOD2 is one of the main targets of Sirt3 287 
which is deacetylated and activated in response to oxidative stress [25]. Its activity (Figure 288 
4C) and expression (Figure 4D, G) showed to follow the same pattern: increase in MDA-S3 289 
cells in both normoxia and hyperoxia compared to MDA-C cells, and decrease upon hyperoxic 290 
treatment in both MDA-C and MDA-S3 cells. On the other hand, SOD1 activity was lower in 291 
MDA-S3 cells in both normoxia and hyperoxia, and was even lower in both MDA-C and MDA-292 
S3 cells upon hyperoxia (Figure 4E). In the case of Cat, only MDA-S3 cells had increased Cat 293 
expression in both normoxia and hyperoxia compared to MDA-C cells (Figure 4F, G). Overall, 294 
we can conclude that Sirt3 induces mtROS, as well as the expression and/or activity of several 295 
proteins involved in antioxidative response, whereas the hyperoxic treatment increases 296 
cellular ROS and decreases antioxidative response regardless of the Sirt3 expression. 297 
 298 
 299 
Figure 4. Overexpressed Sirt3 is not associated with a hyperoxic effect on ROS 300 
production and antioxidative enzymes in MDA-MB-231 cells. (A) Mitochondrial ROS 301 
production in MDA-C and MDA-S3 cells under normoxic and hyperoxic conditions 302 
measured with MitosoxRed dye: MDA-S3 vs. MDA-C (ap<0.001), hyperoxia vs. 303 
normoxia (***p<0.001). (B) Cytosolic ROS production in MDA-C and MDA-S3 cells 304 
under normoxic and hyperoxic conditions measured with DHE dye: hyperoxia vs. 305 
normoxia (***p<0.001). (C) MnSOD (SOD2) activity in MDA-C and MDA-S3 cells under 306 
normoxic and hyperoxic conditions: MDA-S3 vs. MDA-C (ap<0.001), hyperoxia vs. 307 
normoxia (***p<0.001). (D) SOD2 protein expression in MDA-C and MDA-S3 cells 308 
under normoxic and hyperoxic conditions: MDA-S3 vs. MDA-C (ap<0.05), hyperoxia vs. 309 
normoxia (***p<0.01). (E) CuZnSOD (SOD1) activity in MDA-C and MDA-S3 cells under 310 
normoxic and hyperoxic conditions: MDA-S3 vs. MDA-C (ap<0.001), hyperoxia vs. 311 
normoxia (*p<0.05). (F) Catalase (Cat) protein expression in MDA-C and MDA-S3 cells 312 
under normoxic and hyperoxic conditions: MDA-S3 vs. MDA-C (ap<0.01). Data are 313 
presented as mean ± S.D. Experiments were repeated at least three times and 314 
representative data are shown. (G) Immunoblots of SOD2 and Cat protein expression 315 
in MDA-C and MDA-S3 cells under normoxic and hyperoxic conditions. Amido black 316 
was used as a loading control. 317 
Both overexpressed Sirt3 and hyperoxic treatment increase the expression of γH2A.X in 318 
MDA-MB-231 cells. Following the observed higher ROS upon either Sirt3 or hyperoxic 319 
treatment and induced antioxidative enzyme system in MDA-S3 cells in both normoxia and 320 
hyperoxia, analysis of γH2A.X (a marker of double-strand DNA (dsDNA) breaks [26]) protein 321 
expression in MDA-C and MDA-S3 cells was performed. A significant increase of dsDNA breaks 322 
was observed upon Sirt3 expression in both normoxia and hyperoxia compared to MDA-C 323 
cells and was further induced upon hyperoxic treatment in both MDA-C and MDA-S3 cells 324 
(Figure 5A). Cellular localization and the strength of the γH2A.X fluorescence signal were also 325 
analyzed by immunofluorescence using a confocal microscope. Stronger intensity of the 326 
γH2A.X fluorescence signal was observed in both MDA-C and MDA-S3 cells after hyperoxic 327 
treatment, with an even stronger signal in the MDA-S3 cells (Figure 5B). Overlay image 328 
confirmed the localization of γH2A.X in the nucleus. Thus, we can conclude that both Sirt3 329 
and hyperoxia increase the formation of dsDNA breaks. 330 
 331 
  332 
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Figure 5. Both overexpressed Sirt3 and hyperoxic treatment increase the expression 335 
of γH2A.X in MDA-MB-231 cells. (A) Densitometry analysis and immunoblots of 336 
γH2A.X protein expression in MDA-C and MDA-S3 cells under normoxic and hyperoxic 337 
conditions: MDA-S3 vs. MDA-C (ap<0.05), hyperoxia vs. normoxia (***p<0.001). Data 338 
are presented as mean ± S.D. Amido black was used as a loading control. Experiments 339 
were repeated at least three times and representative data are shown. (B) 340 
Representative confocal image of γH2A.X (green) in nucleus (blue; DAPI). 341 
Mitochondria were detected with MitoTracker Deep Red. Overlay image shows an 342 
overlap of the γH2A.X and nuclear staining. 343 
Overexpressed Sirt3 increases the mitotic index in normoxia, whereas both Sirt3 and 344 
hyperoxia increase timp-1 gene expression and reduce colony-forming capacity in MDA-MB-345 
231 cells. Since we observed higher expression of γH2A.X in MDA-S3 cells and upon the 346 
hyperoxic treatment, and DNA damage is known to often cause cell cycle arrest and no proper 347 
cell division [27], we next determined mitotic index, timp-1 gene expression and colony-348 
forming ability of the transfected cells. MDA-S3 cells showed a higher mitotic index in 349 
normoxic conditions than control cells, whereas hyperoxia reversed this effect of Sirt3 and 350 
reduced mitotic index in both control and MDA-S3 cells (Figure 6A). Due to the observed 351 
combined negative effect of Sirt3 and hyperoxia on the mitotic index, we also determined the 352 
expression of the timp-1 gene, which is known as an inhibitor of metalloproteinases and its 353 
increased expression is associated with consequential reduction of cellular invasiveness in 354 
MDA-MB-231 cells-derived tumors [28,29]. The results of the qPCR analysis showed that 355 
MDA-S3 cells have a 2-fold higher expression of the timp1 gene in normoxia and 5-fold higher 356 
in hyperoxia compared to MDA-C (Figure 6B). Hyperoxia also induced its expression in MDA-357 
C cells compared to normoxia (1,5-fold). The pattern observed in mitotic index analysis was 358 
also expected in a colony-forming assay, however, Sirt3 expression reduced colony-forming 359 
ability in both normoxic and hyperoxic conditions, and hyperoxia markedly amplified this 360 
negative effect in both MDA-C and MDA-S3 cells (Figure 6C, D). Overall, we can conclude that 361 
both Sirt3 and hyperoxia, alone or in combination, negatively impact the proliferation 362 
characteristics of MDA-MB-231 cells. 363 
 364 
Figure 6. Overexpressed Sirt3 increases the mitotic index in normoxia, whereas both 365 
Sirt3 and hyperoxia reduce colony-forming capacity and increase timp-1 gene 366 
expression in MDA-MB-231 cells. (A) Percentage of MDA-C and MDA-S3 cells in 367 
mitosis (mitotic index) under normoxic and hyperoxic conditions: MDA-S3 vs. MDA-C 368 
(ap<0.01, bp<0.05), MDA-C hyperoxia vs. normoxia (**p<0.01), MDA-S3 hyperoxia vs. 369 
normoxia (***p<0.001). (B) Real-time PCR analysis of timp-1 gene expression in MDA-370 
C and MDA-S3 cells under normoxic and hyperoxic conditions: MDA-S3 vs. MDA-C 371 
(ap<0.01), hyperoxia vs. normoxia (**p<0.01). Data are presented as fold-change ± 372 
S.E., and normalized to control group. β-actin was used as the endogenous control. 373 
(C) Representative plates of colonies stained with crystal violet. (D) The number of 374 
colonies formed by MDA-C and MDA-S3 cells under normoxic and hyperoxic 375 
conditions: MDA-S3 vs. MDA-C (ap<0.001), MDA-C hyperoxia vs. normoxia 376 
(***p<0.001), MDA-S3 hyperoxia vs. normoxia (**p<0.01). Data for (A) and (D) are 377 
presented as mean ± S.D. Experiments were repeated at least three times and 378 
representative data are shown.  379 
Overexpressed Sirt-3 is associated with hyperoxia-induced apoptosis in MDA-MB-231 cells. 380 
Due to the inhibitory effect of Sirt3 and hyperoxia on mitotic index and CFU analysis, and 381 
increased DNA damage, we aimed to analyze apoptosis rate with an Annexin V-FITC Apoptosis 382 
Kit in transfected cells as a possible outcome of all the observed parameters. The FACS 383 
analysis showed an increased percentage of apoptotic cells in the MDA-S3 cells compared to 384 
MDA-C cells in normoxia (Figure 7A, B), which was further enhanced by hyperoxic treatment. 385 
Interestingly, MDA-C cells did not show an increase in the number of apoptotic cells after 386 
hyperoxic treatment. Thus, we can conclude that hyperoxia-induced apoptosis is associated 387 




Figure 7. Overexpressed Sirt-3 is associated with hyperoxia-induced apoptosis in 392 
MDA-MB-231 cells. (A) Percentage of MDA-C and MDA-S3 cells in late apoptosis under 393 
normoxic and hyperoxic conditions: MDA-S3 vs. MDA-C (ap<0.001), MDA-S3 hyperoxia 394 
vs. normoxia (***p<0.001). Data are presented as mean ± S.D. Experiments were 395 
repeated at least three times and representative data are shown. (B) Dot plot diagrams 396 
of MDA-C and MDA-S3 cells in apoptosis under normoxic and hyperoxic conditions 397 
quantified by FACS, after Annexin V-FITC and PI labelling: intact cells in the lower-left 398 
quadrant, early apoptotic cells in the lower-right quadrant, late apoptotic or necrotic 399 
cells in the upper-right quadrant, and necrotic cells in the upper-left quadrant. 400 
Experiments were repeated at least three times and representative data are shown. 401 
Overexpressed Sirt3 and hyperoxia are associated with formation of multinucleated cells in 402 
MDA-MB-231 cells. Since MDA-S3 cells in normoxia had higher mitotic index but lower CFU, 403 
this prompted us to look into cellular morphology in more detail. For this reason, nuclei of 404 
live cells were stained with Hoechst and mitochondria with NAO. We noticed the presence of 405 
multinucleated cells (MNCs), i.e. giant cells with three or more nuclei in the MDA-S3 cells 406 
(Figure 8A). We also analyzed morphology of the colonies in both normoxic and hyperoxic 407 
conditions formed in the CFU assay, and numerous MNCs were observed in MDA-S3 cells, 408 
which were even more frequent upon hyperoxic conditions (Figure 8B). On the other hand, 409 
we could barely observe MNCs in the MDA-C cells. Thus, we can conclude that Sirt3 and 410 
hyperoxia are associated with formation of MNCs in MDA-MB-231 cell line. 411 
A 412 
 413 
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Figure 8. Overexpressed Sirt3 and hyperoxia are associated with formation of 417 
multinucleated cells in MDA-MB-231 cells. (A) Fluorescence microscopy images of live 418 
MDA-C and MDA-S3 cells in normoxic conditions. Nuclei were detected with Hoechst 419 
(blue), and mitochondria with NAO (green). Multinucleated cells in MDA-S3 are 420 
marked with white arrows. (B) Morphology of the MDA-C and MDA-S3 cells under 421 
normoxic and hyperoxic conditions in the colony forming assay. Multinucleated cells 422 
in MDA-S3 are marked with red arrows. 423 
Overall, although Sirt3 improved several mitochondrial properties, such as mitochondrial 424 
mass and potential, metabolic activity, Ldh-A expression and antioxidative defense (SOD2, 425 
Cat), it also increased mtROS and timp-1 expression, thus diminishing the ability of the MDA-426 
MB-231 cells to form colonies, induced formation of multinucleated cells as well as apoptotic 427 
cell death. These effects were even more pronounced upon hyperoxic treatment, thus 428 
pointing towards combined negative effect of Sirt3 and hyperoxia on MDA-MB-231 cells.  429 
Discussion 430 
Most breast cancer cell lines have very low level of mitochondrial protein Sirt3, which is 431 
known to have either oncogenic or tumor-suppressive role in different types of cancer [8]. 432 
This prompted us to explore the role of Sirt3 in TNBC cell line MDA-MB-231 upon elevated 433 
oxidative stress, i.e. hyperoxia (95% O2). To carry out this study, we transfected the cells with 434 
the plasmid carrying the sirt3 gene and analyzed its effect on various mitochondrial and 435 
tumorigenic characteristics in normoxia and hyperoxia. 436 
Sirt3 overexpressed in MDA-MB-231 cells was increased upon hyperoxic treatment (Figure 1), 437 
most likely due to the elevated oxidative stress which resulted in enhancement of Sirt3 438 
activity, deacetylation of mitochondrial enzymes involved in defense against oxidative stress 439 
and consequent protection from ROS, as demonstrated earlier [30]. To defend the cells from 440 
oxidative stress, the liposomes containing both Cat and SOD2 showed to have greater 441 
protection compared to liposomes containing only one of these two enzymes [31]. Previous 442 
studies showed that an increase in ROS stimulates sirt3 transcription, leading to 443 
posttranslational regulation and activation of SOD2 [25]. This is confirmed in our study by the 444 
increased mtROS and elevated SOD2 level in MDA-S3 cells (Figure 4A, C, D). Although cancer 445 
cells usually have increased ROS compared to normal cells, elevating intracellular ROS to toxic 446 
levels can activate various ROS-induced cell death pathways, or inhibit cancer cell resistance 447 
to chemotherapy (reviewed in [32]). Also, in the apoptosis pathway, mitochondrial potential 448 
is decreased, i.e. mitochondrial membrane permeability is increased, and pro-apoptotic 449 
factors are released from the mitochondria (reviewed in [32]). Since we also observed lower 450 
mitochondrial potential upon hyperoxic treatment compared to normoxia in both MDA-C and 451 
MDA-S3 cells (Figure 2B) as well as higher apoptosis rate in MDA-S3 cells (Figure 7), we can 452 
assume that the hyperoxia-induced high cytosolic and mtROS levels (Figure 4A, B) are indeed 453 
toxic for these cells, resulting in disruption of the whole antioxidant system, as observed 454 
through lower SOD2 and SOD1 activity upon hyperoxia (Figure 4C, E). The lower activity of 455 
the antioxidant enzyme SOD1 in MDA-S3 cells (Figure 4E) is in correlation with a previous 456 
study which showed that loss of SOD2 correlates with the overexpression of SOD1 [33], as 457 
well as that SOD2 reduction in breast cancer occurs rapidly following oncogenic activation, 458 
which was in our study reverted by Sirt3 expression. The third antioxidative enzyme, Cat, has 459 
enhanced expression in MDA-S3 cells, independent of hyperoxic treatment (Figure 4F). There 460 
are indications that increased levels of Cat could contribute to the improved treatment of 461 
breast cancer [34]. Accordingly, the role of Sirt3 to enhance Cat expression may indicate its 462 
tumor suppressive role in these cells. Therefore, we can assume that higher expression of Cat 463 
and increased SOD2 activity, with lower activity of SOD1 contributes to the mitigation of 464 
tumorigenic characteristics of MDA-MB-231 cells upon Sirt3 expression, whereas hyperoxia 465 
induces toxic levels of ROS which disrupt antioxidative defense and mitochondrial potential 466 
and finally have pro-apoptotic effects. 467 
The main source of ROS in cell is the mitochondrial respiratory chain which is also a "target" 468 
for the deleterious effects of ROS [35]. It is known that Sirt3 activates the respiratory 469 
complexes responsible for the formation of ROS [36], and that it regulates numerous 470 
mitochondrial enzymes involved in energy metabolism processes [37]. Thus, the increased 471 
metabolic activity which we observed in the MDA-S3 cells was expected (Figure 3A). Sirt3 is 472 
also involved in metabolism-related regulation of tumor cell growth, i.e. in most cases it 473 
reduces the so-called Warburg effect, a metabolic sign of many tumors defined as the aerobic 474 
glycolysis [38]. However, Warburg-promoting effects of this enzyme have also been 475 
confirmed (reviewed in [39]). Improved mitochondrial mass and potential (Figure 2), higher 476 
metabolic activity and Ldh-A expression as well as lower PGC-1α expression (Figure 3) in the 477 
MDA-S3 cells in normoxic conditions suggest that Sirt3 has a potential to induce the aerobic 478 
glycolysis in these cells. Ldh-A is upregulated in many cancers and is important for tumor 479 
initiation and progression [40]. On the other hand, lower Ldh-A expression (Figure 3C) 480 
associated with higher mitochondrial mass but lower mitochondrial potential (Figure 2), 481 
higher ROS production (Figure 4) and apoptosis rate upon combined hyperoxic treatment and 482 
Sirt3 expression is in correlation with an earlier study showing that Ldh-A-silenced cells 483 
accelerate oxygen consumption and have higher ROS, swollen mitochondria, and finally 484 
undergo apoptosis [40]. Thus, the combined effect of hyperoxia and Sirt3 expression on the 485 
reduction of Ldh-A expression in MDA-MB-231 cells further indicates their tumor-suppressive 486 
effect. We also analyzed the expression of Sirt1, a protein involved in regulation of metabolic 487 
responses which can be found in both nucleus and cytoplasm [20]. Besides its role in 488 
metabolic regulation, Sirt1 was also shown to be directly related to the DNA damage response 489 
and can recruit repair proteins to dsDNA breaks sites and modulate their activity by 490 
deacetylating them [21]. Therefore, higher Sirt1 expression in MDA-S3 cells and upon 491 
hyperoxic treatment (Figure 3B, E), both of which are associated with higher ROS (Figure 4) 492 
and dsDNA damage (Figure 5), is in accordance to the mentioned role of Sirt1 in oxidative 493 
stress. 494 
Although mitochondrial analyses indicate that Sirt3, as a mitochondrial protein, succeeds in 495 
improving mitochondrial function of the MDA-MB-231 cells, the cells ultimately fail to divide 496 
and create colonies (Figure 6C, D). This is most likely due to the excessive DNA damage (Figure 497 
5) resulting from the high concentration of ROS (Figure 4A, B). Excessive DNA damage often 498 
causes cell cycle arrest and no proper exit from mitosis and cell division [27]. In hyperoxia, 499 
both MDA-C and MDA-S3 cells showed pronounced decline in proliferation potential, 500 
consistent with other results suggesting tumor suppressor effects of hyperoxia on breast 501 
cancer cells [41]. Hyperoxia studies to date have considered whether hyperoxia acts as a 502 
tumor promoter or suppressor. Because oxygen is required for all major wound healing 503 
processes, it was thought that hyperoxia would promote tumor growth, but recent studies 504 
confirmed the inhibitory effects of hyperoxia on tumors (reviewed in [41]). We also 505 
performed quantitative RT-PCR to examine the effect of Sirt3 on timp-1, a main inhibitor of 506 
matrix metalloproteinase 9 (MMP-9) which drives malignant progression and metastasis of 507 
basal-like TNBC [29,42]. We found that Sirt3, and especially under hyperoxia, increases timp-508 
1 gene expression (Figure 6B), which further confirms their tumor-suppressive role in MDA-509 
MB-231 cells, since more recent studies point towards inhibitory role of timp-1 on cellular 510 
invasiveness of these cells [28]. Since MDA-S3 cells showed reduced number of colonies, as 511 
well as further reduction of colony number upon hyperoxia, we monitored also the mitotic 512 
index. MDA-S3 cells showed higher mitotic index in normoxia (Figure 6A) whereas, in 513 
hyperoxia, it followed the CFU pattern. This may be explained by the very interesting 514 
observation in this study that Sirt3 expression induced formation of multinucleated cells 515 
(MNCs; Figure 8). A number of studies stress out the importance of understanding the cause 516 
of their appearance, especially because they can arise spontaneously in the TNBC with mutant 517 
p53, and are metabolically very active (reviewed in [43]). Since in our study the MDA-S3 cells 518 
had higher mitotic index but lower colony forming ability, the most probable scenario for the 519 
formation of MNCs is the “mitotic slippage”, a phenomenon in which cells, due to prolonged 520 
mitotic arrest, exit mitosis without undergoing cytokinesis and become multinucleated 521 
(reviewed in [44]). Stressful conditions, like hypoxia, ionizing radiation and chemotherapeutic 522 
drugs increase the proportion of polyploidy and MNCs. p53 mutant cells often try to avoid 523 
senescence and apoptosis by forming MNCs (reviewed in [44]). In our case, we did not 524 
observe senescence phenotype in MDA-MB-231 cells (data not shown), but the apoptosis 525 
analysis clearly showed that cells expressing Sirt3 have higher apoptosis rate (Figure 7), and 526 
this effect is even more pronounced upon hyperoxic treatment. Therefore, we can assume 527 
that some cells expressing Sirt3 enter apoptosis, whereas the other ones try to avoid 528 
apoptosis by forming MNCs (Figure 8). As pointed earlier and showed also now here, these 529 
MNCs appear to be physiologically stressed with elevated ROS and lower mitochondrial 530 
membrane potential [45]. The fact that MDA-S3 cells exhibited such increase of MNCs points 531 
toward negative effect of Sirt3 on these cells, which then consequently impacts their 532 
proliferation. 533 
Conclusion 534 
Although Sirt3 appeared to improve mitochondrial properties by increasing mitochondrial 535 
mass and potential, metabolic activity (Warburg effect) and antioxidative defense (SOD2, 536 
Cat), it also increased mitochondrial ROS, induced DNA damage, timp-1 expression, formation 537 
of multinucleated cells and apoptosis, and markedly reduced the proliferation of MDA-MB-538 
231 cells. All these negative effects on the cells were even more evident upon hyperoxic 539 
treatment, which also reversed some effects of Sirt3. Finally, it can be concluded that Sirt3 540 
and hyperoxia have a common tumor suppressor effect in the MDA-MB-231 breast cancer 541 
cell line, and that additional mechanisms that influence this role in tumor cell proliferation 542 
and invasiveness reduction should be studied in TNBC. 543 
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